Experts from the Russian Ministry of Health have included the TRIAZAVIRIN® antiviral drug in the guidelines "Prevention, Diagnosis and Treatment of the Novel Coronavirus Infection COVID-19" (version No. 19 dated 27/5/2025).
TRIAZAVIRIN® is the only drug recommended by the Russian Ministry of Health for both treatment and prevention of COVID-19.
The mechanism of TRIAZAVIRIN® action involves inhibiting viral RNA synthesis and genomic fragment replication, thereby disrupting the viral proteins life cycle and providing direct antiviral effect.
The results of a multicenter randomized clinical trial have established the efficacy and safety of TRIAZAVIRIN® in the treatment of patients with COVID-19.
TRIAZAVIRIN® is used for the treatment of patients with COVID-19 at a dose of 250 mg 5 times a day for 10 days.
The prophylactic efficacy of TRIAZAVIRIN® has also been established by the results of a multicenter randomized clinical trial, which found that the relative risk of infection in the group taking TRIAZAVIRIN® for prevention was 88.96% lower than in the control group. In terms of safety, the drug was not different from placebo.
The drug is used at a dose of 250 mg once a day for 10 days to prevent COVID-19.
The updated guidelines for drug therapy of COVID-19 have been sent to regional healthcare providers across Russia to inform outpatient and inpatient practitioners who provide medical care to patients.